Literature DB >> 20675158

COX-2 over-expression correlates with VEGF and tumour angiogenesis in canine mammary cancer.

Felisbina L Queiroga1, Isabel Pires, Margarida Parente, Hugo Gregório, Carlos S Lopes.   

Abstract

This study was designed to investigate the possible roles of cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in canine mammary cancer angiogenesis. Immunohistochemistry was performed on 70 tumours (28 benign and 42 malignant) in order to detect COX-2 and VEGF expression. Microvessel density (MVD) was determined by CD31 immunolabelling to assess tumour angiogenesis. There was a significantly higher expression of COX-2 (P<0.001), VEGF (P<0.001) and MVD (P<0.001) in malignant compared to benign tumours. In the malignant group, the MVD of COX-2 positive tumours was significantly higher than that of COX-2 negative tumours (P=0.026). A similar association was observed for VEGF (P<0.001) positive tumours. The results from this study suggested that over-expression of COX-2 and VEGF may contribute to increased angiogenesis and aggression in malignant tumours.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20675158     DOI: 10.1016/j.tvjl.2010.06.022

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  10 in total

1.  Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study.

Authors:  S Anthony Kahn; Christine M Mullin; Louis-Philippe de Lorimier; Kristine E Burgess; Rebecca E Risbon; Rogers M Fred; Kenneth Drobatz; Craig A Clifford
Journal:  Can Vet J       Date:  2013-03       Impact factor: 1.008

2.  Predictors of recurrence in breast cancer subtypes with negative lymph node in a Chinese population.

Authors:  Xia Liu; Yong Guan; Wei Zhang; Shan Liu; Junjun Liu; Li Wang; Yun Niu
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

3.  Use of a colorimetric assay to evaluate the proliferation of canine mammary tumor cells exposed to propofol.

Authors:  Martina Argano; Raffaella De Maria; Katrin Rodlsberger; Paolo Buracco; M Paula Larenza Menzies
Journal:  Can J Vet Res       Date:  2019-04       Impact factor: 1.310

4.  Inhibiting the proliferation and metastasis of hilar cholangiocarcinoma cells by blocking the expression of vascular endothelial growth factor with small interfering RNA.

Authors:  Ke Xiao; Zhengxiao Ouyang; Hui-Huan Tang
Journal:  Oncol Lett       Date:  2018-05-30       Impact factor: 2.967

Review 5.  The role of COX expression in the prognostication of overall survival of canine and feline cancer: A systematic review.

Authors:  Hugo Gregório; Tomás R Magalhães; Isabel Pires; Justina Prada; Maria I Carvalho; Felisbina L Queiroga
Journal:  Vet Med Sci       Date:  2021-03-10

6.  Salvianolic Acid B, a potential chemopreventive agent, for head and neck squamous cell cancer.

Authors:  Yuan Zhao; Yinhan Guo; Xinbin Gu
Journal:  J Oncol       Date:  2010-12-20       Impact factor: 4.375

Review 7.  Current biomarkers of canine mammary tumors.

Authors:  Ilona Kaszak; Anna Ruszczak; Szymon Kanafa; Kamil Kacprzak; Magdalena Król; Piotr Jurka
Journal:  Acta Vet Scand       Date:  2018-10-29       Impact factor: 1.695

8.  Next-generation RNA sequencing of FFPE subsections reveals highly conserved stromal reprogramming between canine and human mammary carcinoma.

Authors:  Parisa Amini; Sina Nassiri; Julia Ettlin; Alexandra Malbon; Enni Markkanen
Journal:  Dis Model Mech       Date:  2019-08-08       Impact factor: 5.758

Review 9.  Know Thy Model: Charting Molecular Homology in Stromal Reprogramming Between Canine and Human Mammary Tumors.

Authors:  Enni Markkanen
Journal:  Front Cell Dev Biol       Date:  2019-12-17

10.  Intratumoral CD3+ T-lymphocytes immunoexpression and its association with c-Kit, angiogenesis, and overall survival in malignant canine mammary tumors.

Authors:  Maria Isabel Carvalho; Isabel Pires; Marlene Dias; Justina Prada; Hugo Gregório; Luis Lobo; Felisbina Queiroga
Journal:  Anal Cell Pathol (Amst)       Date:  2015-08-05       Impact factor: 2.916

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.